Navigation Links
Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility

SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that due to the successful scale-up of the supply of Osteocel, NuVasive has accelerated the transfer of the processing of Osteocel Plus from Osiris Therapeutics (Nasdaq: OSIR) to its own exclusive supply chain.

Since the May 2008 announcement of the original transaction, the companies have successfully worked to increase production and transfer the technical know-how and related intellectual property to NuVasive. Due to NuVasive's confidence in its ability to supply product to support its planned sales growth of Osteocel Plus, the companies have decided to eliminate the performance contingencies applicable to $30 million of the $45 million in remaining milestones. The $30 million in milestones is scheduled to be paid as follows:

                       Date of Payment         Payment Value
                       March 31, 2009              $5.0M
                       June 30, 2009              $12.5M
                       September 30, 2009         $12.5M
                       Total                      $30.0M

The terms applicable to the remaining $15 million milestone payment, which is due upon NuVasive achieving $35 million in cumulative sales of Osteocel, remain unchanged. To date, NuVasive has made a total of $40 million in up-front and milestone payments. The total potential consideration of $85 million remains unchanged.

Under the new terms, NuVasive immediately assumes control of production. NuVasive has selected AlloSource as its exclusive supplier of Osteocel Plus. AlloSource is one of the nation's largest tissue providers and has already started supplying Osteocel Plus. AlloSource has been working to scale up its production since last summer and NuVasive expects the AlloSource supply relationship to provide an efficient and consistent stream of supply. NuVasive will not assume ownership of the Osiris tissue processing facility.

NuVasive reiterates its previous guidance of $28 million in Osteocel Plus revenue in 2009 with no change in profitability targets. NuVasive notes that the transfer of processing will support its ability to meet or exceed 2009 Osteocel Plus sales goals and fuel anticipated revenue growth to $100 million and beyond.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of biologics, cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel Plus, and the Progentix products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive revenue projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that NuVasive may encounter unanticipated difficulty integrating the Osteocel product into its product line; the risk that NuVasive may be unable to generate expected revenues from Osteocel; the uncertain process of seeking regulatory approval or clearance for NuVasive's products of devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Kevin C. O'Boyle
    EVP & Chief Financial Officer
    NuVasive, Inc.

    Patrick F. Williams
    Vice President, Finance & Investor Relations
    NuVasive, Inc.

    Jason Rando
    The Ruth Group

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Martek and Ragasa Sign Multi-Year Exclusive Supply Agreement
2. MedClean Technologies, Inc. Awarded MedAssets Supply Chain Systems Contract
3. Doctor Diabetic Supply, Inc. Renews its ACHC Accreditation
4. SAFC(R) Underlines Commitment to Pharmaceutical Supply Chain Quality With New Global Vendor Audit Services
5. Convection Cooled 150-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards
6. MAGNET Selects MHS as Preferred Vendor of Leading Edge Supply Chain Solutions
7. Irelands EHA Soft Solutions Selected to Supply Risk Management and Mitigation Software to Quality Employment Credentialing for Healthcare Workforce
8. New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services
9. SIS Offers Increased Financial and Operational Efficiencies with Pyxis Supply Technologies
10. Top Performers in UHC 2009 Supply Chain Performance Excellence Collaborative
11. Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology company ... health programs and interventions via mobile devices that provide a framework for the ...
(Date:10/13/2015)... Houston, TEXAS (PRWEB) , ... October 13, 2015 ... ... firm and solution provider of IBM software products, introduced a new company, RightSensor™ ... sensor systems and data communications capability. RightSensor™ provides a fully-managed approach for ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of its ... with, participate in local fitness & sporting events, and stay motivated. Users ... medical costs drive us to get more serious about fitness and wellness, individuals are ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... kind product that targets the unique health needs of new moms. Postnatal ... Pregnancy Association ( ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 ...
(Date:10/13/2015)... ... 13, 2015 , ... California Southern University has named Dr. ... her Doctor of Nursing Practice from the renowned Johns Hopkins University—comes to CalSouthern ... Dr. McLeod’s long and successful nursing practice included a variety of patient care, ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  Measurement in accountable care programs is essential ... but gaps in measurement can result in missed ... A new, peer-reviewed study published in ... explores measurement gaps for high-priority conditions and identifies ... --> --> "These gaps in ...
(Date:10/13/2015)... Mass. , Oct. 13, 2015  SeraCare Life ... manufacturers, announced today that the company,s precision medicine business ... line of reference materials for next-generation sequencing (NGS)-based tumor ... Mix-I (AF1-10) contains the same mixture of mutations in ... previously launched AF20 mix , but is offered ...
(Date:10/13/2015)... , Oct. 9, 2015 Research and Markets ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), ... Mangoes, Flowers, Others), & by Region - Forecasts to ... --> --> The ... last few years. In terms of value, the market ...
Breaking Medicine Technology: